Pfizer Inc (PFE)
25.37
-0.05
(-0.20%)
USD |
NYSE |
Apr 18, 15:50
Pfizer Cash from Financing (TTM): 26.07B for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 26.07B |
September 30, 2023 | 15.61B |
June 30, 2023 | 13.63B |
March 31, 2023 | -11.03B |
December 31, 2022 | -14.83B |
September 30, 2022 | -13.17B |
June 30, 2022 | -8.51B |
March 31, 2022 | -13.59B |
December 31, 2021 | -9.816B |
September 30, 2021 | -20.25B |
June 30, 2021 | -21.97B |
March 31, 2021 | -10.26B |
December 31, 2020 | -9.649B |
September 30, 2020 | 1.698B |
June 30, 2020 | 7.792B |
March 31, 2020 | -2.218B |
December 31, 2019 | -8.485B |
September 30, 2019 | -12.45B |
June 30, 2019 | -17.13B |
March 31, 2019 | -18.19B |
December 31, 2018 | -20.44B |
September 30, 2018 | -17.78B |
June 30, 2018 | -18.08B |
March 31, 2018 | -19.16B |
December 31, 2017 | -13.35B |
Date | Value |
---|---|
September 30, 2017 | -11.92B |
June 30, 2017 | -11.87B |
March 31, 2017 | -6.964B |
December 31, 2016 | -9.228B |
September 30, 2016 | -8.209B |
June 30, 2016 | -6.81B |
March 31, 2016 | -10.60B |
December 31, 2015 | -10.41B |
September 30, 2015 | -12.24B |
June 30, 2015 | -14.87B |
March 31, 2015 | -15.03B |
December 31, 2014 | -10.19B |
September 30, 2014 | -12.80B |
June 30, 2014 | -15.55B |
March 31, 2014 | -17.54B |
December 31, 2013 | -14.98B |
September 30, 2013 | -15.46B |
June 30, 2013 | -13.12B |
March 31, 2013 | -12.06B |
December 31, 2012 | -16.00B |
September 30, 2012 | -16.02B |
June 30, 2012 | -16.76B |
March 31, 2012 | -17.71B |
December 31, 2011 | -20.61B |
September 30, 2011 | -15.44B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-21.97B
Minimum
Jun 2021
26.07B
Maximum
Dec 2023
-5.714B
Average
-9.816B
Median
Dec 2021
Cash from Financing (TTM) Benchmarks
Amgen Inc | 21.05B |
Gilead Sciences Inc | -5.125B |
Johnson & Johnson | -15.82B |
Viking Therapeutics Inc | 271.38M |
Moderna Inc | -1.377B |